Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.

摘要: In the Thrombolysis in Myocardial Infarction, Phase II pilot and clinical trial, 908 patients [326 (35.9%) study 582 (64.0%) randomized study] were treated with 150 mg recombinant tissue-type plasminogen (rt-PA) activator combination heparin aspirin, 3,016 [64 (2.1%) 2,952 (97.9%) 100 rt-PA aspirin. Adverse neurological events occurred 23 (2.5%) [nine cerebral infarctions (1.0%), 12 intracerebral hemorrhages (1.3%), two subdural hematomas (0.2%)] 33 (1.1%) [20 (0.7%), 11 (0.4%), (0.1%)]. The difference adverse observed comparing regimens was primarily due to a higher frequency of bleeding among (1.3% versus 0.4%, p less than 0.01). Patients recent (within 6 months) histories stroke not eligible for study, any history cerebrovascular disease declared ineligible early study. small number (89, or 2.3%) disease, intermittent ischemic attacks, who enrolled before stricter eligibility criteria imposed on basis incomplete baseline information experienced an increased hemorrhage compared without such (3.4% 0.5%). Mortality at weeks after presentation had 47.8%. Intracerebral is severe but infrequent complication therapy acute myocardial infarction. combined hemorrhage, hematoma, infarction treatment comparable that other trials thrombolytic agents